OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pakkala on Integrating Local Therapy into HER2+ Breast Cancer Treatment

December 15th 2022

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

Dr. Mercado on the Effect of the COVID-19 Pandemic on Lung Cancer Screening

December 14th 2022

Jorge M. Mercado, MD, discusses the effect of the COVID-19 pandemic on lung cancer screening.

Dr. Susanibar on Important Considerations When Treating Multiple Myeloma

December 14th 2022

Sandra P. Susanibar-Adaniya, MD, discusses important considerations when treating patients with multiple myeloma.

Dr. George on the Importance of Understanding Mutations in Prostate Cancer

December 14th 2022

Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.

Dr. Jim on Real-World Quality of Life Outcomes With Axi-Cel in R/R LBCL

December 14th 2022

Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr. Singal on the FDA Approval of Durvalumab With Tremelimumab in Unresectable HCC

December 13th 2022

Amit Singal, MD, discusses the FDA approval of durvalumab with tremelimumab (Imjudo) in unresectable hepatocellular carcinoma.

Dr Reshef on Data From the BMT CTN 1703 Trial Evaluating Post-Transplant GVHD Prophylactic Regimens

December 13th 2022

Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.

Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual Anemia

December 13th 2022

Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.

Dr Topp on the Efficacy of Glofitamab Plus R-CHOP in Previously Untreated DLBCL

December 12th 2022

Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.

Dr. Spira on the FDA Approval of Adagrasib in KRAS G12C–mutant NSCLC

December 12th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the FDA approval of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCL

December 12th 2022

Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.

Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple Myeloma

December 12th 2022

Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr Berdeja on the Safety and Efficacy of BMS-986393 in R/R Multiple Myeloma

December 11th 2022

Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.

Dr. Oliveira on the Examination of Camizestrant Vs Fulvestrant in ER+/HER2- Breast Cancer

December 9th 2022

Mafalda Oliveira, MD, PhD, discusses the examination of camizestrant vs fulvestrant in estrogen receptor-positive, HER2-negative advanced breast cancer.

Dr. Patel on Key Updates from First-Line Trials in NSCLC

December 9th 2022

Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.

Dr. Verschraegen on the Need to Address TRAEs of Immunotherapy in Melanoma

December 9th 2022

Claire F. Verschraegen, MD, discusses the need to improve the management of treatment-related adverse effects of immunotherapy in melanoma.

Dr. George on the Use of Niraparib for Patients With BRCA and ATM Mutations in mCRPC

December 9th 2022

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Dr. Sabari on the Importance of Timely Testing for Uncommon Mutations in NSCLC

December 9th 2022

Joshua K. Sabari, MD, discusses the importance of timely testing for uncommon mutations in non–small cell lung cancer.

Dr. Rohs on Databases of Uncommon Mutations in NSCLC

December 9th 2022

Nicholas C. Rohs, MD, discusses databases of uncommon mutations in non–small cell lung cancer

Dr. Mukherjee on the Implications of the FDA Approval of Second-line Liso-cel in LBCL

December 9th 2022

Akash Mukherjee, MD, discusses the implications of the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma.